Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)

Saiama N. Waqar; Clifford Robinson; Anthony J. Olszanski; Alexander Spira; Melissa Hackmaster; Luisa Lucas; Laura Sponton; Hulin Jin; Ursula Hering; Damien Cronier; Marianna Grinberg; Annick Seithel-Keuth; Ivan Diaz-Padilla; Jordan Berlin

doi:10.1007/s10637-022-01226-6

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)

Saiama N. Waqar
, Clifford Robinson
, Anthony J. Olszanski
, Alexander Spira
, Melissa Hackmaster
, Luisa Lucas
, Laura Sponton
, Hulin Jin
, Ursula Hering
, Damien Cronier
, Marianna Grinberg
, Annick Seithel-Keuth
, Ivan Diaz-Padilla
, Jordan Berlin

Washington University St. Louis
Merck KGaA
Vanderbilt University
Virginia Cancer Specialists

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

The article Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors was originally published electronically on the publisher’s internet portal on 12 January 2022 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication.

Original language	English
Pages (from-to)	679
Number of pages	1
Journal	Investigational New Drugs
Volume	40
Issue number	3
DOIs	https://doi.org/10.1007/s10637-022-01226-6
State	Published - Jun 2022

Access to Document

10.1007/s10637-022-01226-6

Fingerprint

Dive into the research topics of 'Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)'. Together they form a unique fingerprint.

Cite this

Waqar, S. N., Robinson, C., Olszanski, A. J., Spira, A., Hackmaster, M., Lucas, L., Sponton, L., Jin, H., Hering, U., Cronier, D., Grinberg, M., Seithel-Keuth, A., Diaz-Padilla, I., & Berlin, J. (2022). Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8). Investigational New Drugs, 40(3), 679. https://doi.org/10.1007/s10637-022-01226-6

@article{a7c4451300e541fdb7169847956cf89c,

title = "Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)",

abstract = "The article Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors was originally published electronically on the publisher{\textquoteright}s internet portal on 12 January 2022 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication.",

author = "Waqar, \{Saiama N.\} and Clifford Robinson and Olszanski, \{Anthony J.\} and Alexander Spira and Melissa Hackmaster and Luisa Lucas and Laura Sponton and Hulin Jin and Ursula Hering and Damien Cronier and Marianna Grinberg and Annick Seithel-Keuth and Ivan Diaz-Padilla and Jordan Berlin",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jun,

doi = "10.1007/s10637-022-01226-6",

language = "English",

volume = "40",

pages = "679",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "3",

}

Waqar, SN, Robinson, C, Olszanski, AJ, Spira, A, Hackmaster, M, Lucas, L, Sponton, L, Jin, H, Hering, U, Cronier, D, Grinberg, M, Seithel-Keuth, A, Diaz-Padilla, I & Berlin, J 2022, 'Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)', Investigational New Drugs, vol. 40, no. 3, pp. 679. https://doi.org/10.1007/s10637-022-01226-6

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8). / Waqar, Saiama N.; Robinson, Clifford; Olszanski, Anthony J. et al.
In: Investigational New Drugs, Vol. 40, No. 3, 06.2022, p. 679.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Author Correction

T2 - Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)

AU - Waqar, Saiama N.

AU - Robinson, Clifford

AU - Olszanski, Anthony J.

AU - Spira, Alexander

AU - Hackmaster, Melissa

AU - Lucas, Luisa

AU - Sponton, Laura

AU - Jin, Hulin

AU - Hering, Ursula

AU - Cronier, Damien

AU - Grinberg, Marianna

AU - Seithel-Keuth, Annick

AU - Diaz-Padilla, Ivan

AU - Berlin, Jordan

PY - 2022/6

Y1 - 2022/6

N2 - The article Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors was originally published electronically on the publisher’s internet portal on 12 January 2022 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication.

AB - The article Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors was originally published electronically on the publisher’s internet portal on 12 January 2022 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication.

UR - https://www.scopus.com/pages/publications/85125368316

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000762343100001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1007/s10637-022-01226-6

DO - 10.1007/s10637-022-01226-6

M3 - Comment/debate

C2 - 35226229

SN - 0167-6997

VL - 40

SP - 679

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors (Investigational New Drugs, (2022), 40, 3, (596-605), 10.1007/s10637-022-01216-8)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this